Project 2, headed by Dr. Derek Abbott, will will test the alternative hypothesis that exaggerated N0D2 signaling leads to chronic intestinal inflammation. This project will investigate the dysregulation of the Nod2 gene at the molecular level. Lack of coordination between inflammatory signaling pathways influences the development of CD. We recently published that the E3 ubiquifin ligase ITCH, causes K63-linked polyubiquitinafion of RIP2, and this event downregulates active NOD2:RIP2 complexes. Mice in which Itch is genetically lost (itchy mice) develop inflammatory disease at mucosal surfaces (including intestinal inflammation). We have data showing that ITCH-/- mice develop gastritis, ileitis and colitis and that drugs that inhibit RIP2 tyrosine phosphorylation, such as tarceva and iressa, inhibit the exaggerated N0D2 responses. The central hypothesis of this project is that ITCH downregulates NOD2;RIP2-induced NFDB signaling, and that CD results when this downregulation is lost.
Aim 1 will study this ITCH-induced ubiquitination event to determine the biochemistry and physiologic function of ITCH-induced RIP2 ubiquitination.
In Aim 2, we will determine the role of tyrosine phosphorylation of R1P2 and the role that pharmacological inhibition of this phosphorylation plays in ITCH-induced R1P2 ubiquitination and N0D2- induced cytokine responses.
In Aim 3, we will characterize the Gl inflammation of the Itchy mouse and will determine whether tarceva or iressa can alleviate chronic intestinal inflammation in these mice. Our preliminary data shows that Itchy mice have increased gastrointestinal permeability. This increased permeability allows MDP leakage into the lamina propria and causes prolonged NFkappaB activation to occur. We hypothesize that tarceva and iressa will inhibit exaggerated lamina propria N0D2 activation in the itchy mice and alleviate the chronic inflammation. The overall objective of this project is to determine the biochemistry of the ITCH:RIP2 interaction, the physiologic significance of this interaction, and most importantly, whether this interaction can be inhibited pharmacologically to ameliorate chronic intestinal inflammation.

Public Health Relevance

CD affects more than 500,000 individuals in the US and incurs significant costs to society. Understanding the precise mechanisms and immune defects that cause the disease will allow us to develop better therapies and begin to develop a cure for this devastating disease.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZDK1-GRB-6 (J1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Case Western Reserve University
United States
Zip Code
Chirieleison, Steven M; Marsh, Rebecca A; Kumar, Prathna et al. (2017) Nucleotide-binding oligomerization domain (NOD) signaling defects and cell death susceptibility cannot be uncoupled in X-linked inhibitor of apoptosis (XIAP)-driven inflammatory disease. J Biol Chem 292:9666-9679
Menghini, Paola; Di Martino, Luca; Lopetuso, Loris R et al. (2017) A novel model of colitis-associated cancer in SAMP1/YitFc mice with Crohn's disease-like ileitis. PLoS One 12:e0174121
Do, Jeong-Su; Kim, Sohee; Keslar, Karen et al. (2017) ?? T Cells Coexpressing Gut Homing ?4?7 and ?E Integrins Define a Novel Subset Promoting Intestinal Inflammation. J Immunol 198:908-915
Cominelli, Fabio; Arseneau, Kristen O; Rodriguez-Palacios, Alexander et al. (2017) Uncovering Pathogenic Mechanisms of Inflammatory Bowel Disease Using Mouse Models of Crohn's Disease-Like Ileitis: What is the Right Model? Cell Mol Gastroenterol Hepatol 4:19-32
Rathkey, Joseph K; Benson, Bryan L; Chirieleison, Steven M et al. (2017) Live-cell visualization of gasdermin D-driven pyroptotic cell death. J Biol Chem 292:14649-14658
Corridoni, D; Rodriguez-Palacios, A; Di Stefano, G et al. (2017) Genetic deletion of the bacterial sensor NOD2 improves murine Crohn's disease-like ileitis independent of functional dysbiosis. Mucosal Immunol 10:971-982
Ley, Klaus; Rivera-Nieves, Jesus; Sandborn, William J et al. (2016) Integrin-based therapeutics: biological basis, clinical use and new drugs. Nat Rev Drug Discov 15:173-83
Grivennikov, Sergei I; Cominelli, Fabio (2016) Colitis-Associated and Sporadic Colon Cancers: Different Diseases, Different Mutations? Gastroenterology 150:808-10
Goodman, W A; Omenetti, S; Date, D et al. (2016) KLF6 contributes to myeloid cell plasticity in the pathogenesis of intestinal inflammation. Mucosal Immunol 9:1250-62
Basson, Abigail; Trotter, Ashley; Rodriguez-Palacios, Alex et al. (2016) Mucosal Interactions between Genetics, Diet, and Microbiome in Inflammatory Bowel Disease. Front Immunol 7:290

Showing the most recent 10 out of 76 publications